You are viewing: North America AI in Oncology Market analysis
Part of: AI in Oncology Market (Global)

The North America AI in Oncology Market was valued at $1044.5 Million in 2024 and projected to reach to $4755.9 Million by 2029, representing a compound annual growth rate of 28.7%. North America's AI in Oncology market is poised for transformative growth through 2029, driven by increasing cancer incidence, healthcare provider adoption of AI diagnostics, and regulatory support for digital health innovations.

North America AI in Oncology Market (2024-2029) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

North America AI in Oncology Market Trends and Insights

  • This robust growth trajectory reflects North America's leadership in healthcare innovation, advanced computational infrastructure, and substantial investment in precision medicine.
  • North America's dominance is driven by early adoption of AI-powered diagnostic and treatment solutions, strong regulatory frameworks, and collaboration between technology companies and oncology centers. The North America market benefits from a mature healthcare ecosystem, high patient awareness, and significant R&D spending across the region.
  • North America's pharmaceutical and medical device companies are increasingly integrating AI into oncology workflows for tumor detection, drug discovery, and personalized treatment planning.
  • Between 2024 and 2029, North America is expected to consolidate its position as the global leader in AI-enabled cancer care, supported by favorable reimbursement policies and growing clinical evidence of AI efficacy in improving patient outcomes..

Key Market Statistics

  • CAGR (2024-2029) 28.7% CAGR
  • Market Size, 2024 ~USD 1044.5 Million
  • Forecast, 2029 ~USD 4755.9 Million
  • Geography North America

North America AI in Oncology Market Overview

Market Leadership Position :

North America commands the largest share of the global AI in Oncology market, with the US alone representing $4,498.6 million in 2024, demonstrating unparalleled market dominance and investment capacity in cancer care innovation.

Exceptional Growth Trajectory :

North America's AI in Oncology market is expanding at a 28.7% CAGR, slightly below the global rate of 29.4%, yet maintaining the largest absolute market value with projected growth from $1,044.5 million to $4,755.9 million by 2029.

Advanced Healthcare Infrastructure :

North America benefits from world-class computational infrastructure, robust regulatory frameworks, and established healthcare systems that accelerate AI adoption in oncology diagnostics, treatment planning, and patient outcomes prediction.

Precision Medicine Investment :

Substantial R&D funding and venture capital investment in North America drive early adoption of AI-powered precision oncology solutions, positioning the region as the innovation hub for next-generation cancer treatment technologies.

North America AI in Oncology Market Dynamics

  • The region's mature healthcare ecosystem, combined with significant pharmaceutical and biotech investments, creates an ideal environment for AI-powered oncology solutions including imaging analysis, drug discovery acceleration, and personalized treatment recommendations. The US market will continue to anchor regional growth, while Canada's expanding healthcare digitalization initiatives contribute meaningful expansion.
  • Integration of AI into existing oncology workflows, coupled with reimbursement model evolution and clinical validation of AI tools, will accelerate market penetration across major healthcare systems and cancer centers throughout North America..

Related Ecosystem

Healthcare Analytics

Top Technologies
  • Machine Learning
  • Natural Language Processing (NLP)
  • Blood Pressure Monitors
  • Computed Tomography (CT)
  • Magnetic Resonance Imaging (MRI)
Top Companies
  • Oracle Corporation
  • PHILIPS HEALTHCARE
  • Siemens healthineers
  • Zensar Technologies Limited
  • EPIC SYSTEMS CORPORATION

    Healthcare It

    Top Technologies
    • Computed Tomography (CT)
    • Machine Learning
    • Magnetic Resonance Imaging (MRI)
    • Natural Language Processing (NLP)
    • Predictive Analytics
    Top Companies
    • CERNER CORPORATION
    • PHILIPS HEALTHCARE
    • Oracle Corporation
    • GE HealthCare Technologies Inc.
    • Siemens healthineers

      Key Takeaways

      • North America's AI in Oncology Market will grow from $1,044.5M (2024) to $4,755.9M (2029) at a 28.7% CAGR.
      • North America leads global adoption of AI-powered diagnostic imaging, treatment planning, and drug discovery in oncology.
      • North America's mature healthcare infrastructure and reimbursement landscape accelerate AI integration across cancer care pathways.
      • North America's strong regulatory environment and clinical validation drive investor confidence and market expansion through 2029.

      AI in Oncology Market Report Scope

      Report Metric Details
      Base Year 2024
      Fastest Growing Segment DEEP LEARNING (Type)
      Forecast Period 2024-2029
      Growth Rate CAGR of 29.4% from 2024 to 2029
      Largest Segment SOLID TUMORS (Cancer Type)
      Market Size Base Year (Billions) ~USD 2.45 (2024)
      Revenue Forecast (Billions) ~USD 8.9 (2029)
      Segments Covered Technology, Type, Application, Cancer Type, End User, Player Type, Deployment Model

      North America AI in Oncology Market Report Segmentation

      7 segment dimensions are covered across the global market.

      By Technology

      • Computer Vision
      • Context-Aware Processing & Computing
      • Image Analysis
      • Machine Learning
      • Natural Language Processing
      • Natural Language Processing (Nlp)

      By Type

      • Adaptive Trial Design & Monitoring
      • AI-Guided Drug Delivery
      • Brain Tumors
      • Breast Cancer
      • Candidate Selection & Validation
      • Chemotherapy
      • Clinical Trial Optimization
      • Colorectal Cancer
      • Combination & Dose Optimization
      • Computed Tomography
      • Computed Tomography (Ct)
      • Deep Learning
      • Digital Pathology & Histopathology
      • Genetic Risk Prediction
      • Hit Identification & Prioritization
      • Hit-To-Lead Identification/Lead Generation
      • Hospitals & Clinics
      • Imaging & Radiology
      • Immunotherapy
      • Intraoperative Guidance & Robotics
      • Intraoperative Guidance And Robotics
      • Laboratories & Diagnostic Centers
      • Lead Optimization
      • Leukemia
      • Liquid Biopsy & Biomarker Detection
      • Long-Term Prediction
      • Lung Cancer
      • Lymphoma
      • Magnetic Resonance Imaging (Mri)
      • Mammography
      • Mental Health & Support Systems
      • Multiple Myeloma
      • Nuclear Imaging
      • Other Healthcare Providers
      • Other Hematologic Malignancies
      • Other Hematological Malignancies
      • Other Imaging Modalities
      • Other Machine Learning Technologies
      • Other Solid Tumors
      • Other Tumors
      • Others Healthcare Providers
      • Patient Education & Empowerment
      • Personalized Treatment Planning
      • Postoperative Analysis & Recovery
      • Precision Medicine & Genomic Analysis
      • Preclinical Testing
      • Predictive Modeling For Human Trials
      • Predictive Modelling For Human Trials
      • Predictive Models For Treatment Response
      • Preoperative Imaging & 3D Modeling
      • Preoperative Imaging And 3D Modeling
      • Prostate Cancer
      • Radiation Therapy
      • Radiomics & Radiogenomics
      • Radiomics And Radiogenomics
      • Recurrence Monitoring
      • Reinforcement Learning
      • Remote Patient Monitoring
      • Specialty Centers
      • Supervised Learning
      • Surgical Planning & Assistance
      • Symptom Management & Virtual Assistance
      • Target Identification & Validation
      • Targeted Therapy
      • Treatment Recommendation Systems
      • Ultrasound
      • Unsupervised Learning
      • X-Ray Imaging

      By Application

      • Data Management & Analytics
      • Diagnosis & Early Detection
      • Drug Development
      • Drug Discovery
      • Other Applications
      • Patient Engagement & Remote Monitoring
      • Post Treatment Surveillance & Survivorship Care
      • Post-Treatment Surveillance & Survivorship Care
      • Treatment Planning & Personalization

      By Cancer Type

      • Hematologic Malignancies
      • Hematological Malignancies
      • Other Cancer Types
      • Other Cancers
      • Others Cancer Types
      • Solid Tumors

      By End User

      • Academic & Research Institutions
      • Government & Regulatory Agencies
      • Healthcare Payers
      • Healthcare Providers
      • Medical Device/ Equipment Companies
      • Medical Device/Equipment Companies
      • Other End Users
      • Pharmaceutical & Biotechnology Companies

      By Player Type

      • Business Process Service Providers
      • Integrated Suite/Platform Providers
      • Niche/Point Solution Providers
      • Technology Providers

      By Deployment Model

      • Cloud-Based Model
      • Hybrid Model
      • On-Premises Model

      Target Audience

      • Healthcare Technology Investors : Identify high-growth investment opportunities in North America's rapidly expanding AI oncology sector, with clear market sizing, growth trajectories, and competitive dynamics to support venture capital and private equity decision-making.
      • Pharmaceutical & Biotech Companies : Understand North American market demand for AI-enabled drug discovery, clinical trial optimization, and personalized treatment solutions to inform R&D investments and commercial strategy in the region's premium oncology market.
      • Healthcare Providers & Hospital Systems : Evaluate AI oncology solutions and vendors operating in North America, with market intelligence on adoption rates, clinical outcomes, and implementation best practices to guide technology procurement and integration decisions.
      • Medical Device & Software Vendors : Access North American market segmentation, competitive positioning, and customer requirements to develop targeted product strategies, pricing models, and go-to-market approaches for AI-powered oncology platforms.
      • Management Consultants & Analysts : Support client engagements in healthcare innovation, digital transformation, and oncology market strategy with authoritative North American market data, growth forecasts, and regional competitive analysis.

      North America vs. other regions

      HowNorth America compares to the other 3 regional blocs covered in this market.

      Europe
      ~USD 3302.2 Million · 29.8% wtd CAGR ·
      Asia Pacific
      ~USD 2741.2 Million · 30.7% wtd CAGR ·
      Latin America
      ~USD 477.8 Million · 28.1% wtd CAGR ·
      Middle East & Africa
      ~USD 237.9 Million · 26.1% wtd CAGR ·

      Countries within North America - compare and drill down

      Country2025 size (native)
      USUSD 4498.6 Million
      CanadaUSD 257.3 Million

      Country market size visualization

      US
      USD 4498.6 Million
      Canada
      USD 257.3 Million

      Reasons to Buy this Report

      • Market Size & Revenue Opportunity : Access comprehensive data on North America's $1,044.5 million market expanding to $4,755.9 million by 2029, with detailed breakdowns by country (US: $4,498.6M, Canada: $257.3M) to identify high-value investment and partnership opportunities.
      • Competitive Intelligence : Understand North America's dominant market position relative to global competitors, with insights into why the region leads in AI oncology adoption, regulatory approval rates, and clinical implementation across major healthcare systems.
      • Strategic Market Entry : Develop go-to-market strategies tailored to North American healthcare dynamics, including reimbursement landscapes, hospital procurement processes, and integration requirements specific to US and Canadian oncology centers.
      • Investment Decision Support : Leverage detailed growth projections and CAGR analysis (28.7%) to support funding decisions, M&A strategies, and resource allocation for AI oncology ventures targeting the world's largest and most lucrative regional market.
      • Technology Adoption Trends : Gain insights into North American adoption patterns for AI diagnostics, treatment planning, and patient monitoring solutions, enabling product development and feature prioritization aligned with regional healthcare provider requirements.

      Frequently asked questions

      What is the projected size of North America's AI in Oncology Market by 2029?

      North America's AI in Oncology Market is projected to reach $4,755.9 million by 2029, growing from $1,044.5 million in 2024.

      What is the CAGR for North America's AI in Oncology Market?

      North America's AI in Oncology Market is expected to grow at a compound annual growth rate (CAGR) of 28.7% from 2024 to 2029.

      Why is North America leading the global AI in Oncology Market?

      North America leads due to advanced healthcare infrastructure, significant R&D investment, early AI adoption, favorable reimbursement policies, and strong regulatory frameworks supporting innovation in cancer care.

      What are the primary applications of AI in North America's oncology sector?

      North America's oncology sector uses AI for diagnostic imaging analysis, treatment planning optimization, drug discovery acceleration, patient outcome prediction, and personalized medicine development.

      Which factors are driving growth in North America's AI in Oncology Market?

      Key drivers include increasing cancer prevalence, demand for precision medicine, clinical validation of AI solutions, growing partnerships between tech and healthcare companies, and expanding insurance coverage for AI-enabled diagnostics.

      RESEARCH METHODOLOGY

      The study involved significant activities to estimate the current size of the AI in oncology. Exhaustive secondary research was done to collect information on the AI in oncology market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the AI in oncology market.

      Secondary Research

      This research study involved the wide use of secondary sources, directories, and databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva; white papers, annual reports, and companies’ house documents; investor presentations; and the SEC filings of companies. The market for the companies offering AI in oncology solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases.

      Various secondary sources were referred to in the secondary research process to identify and collect information related to the study. These sources included annual reports, press releases, investor presentations of AI in oncology vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and technology-oriented perspectives.

      Primary Research

      In the primary research process, various primary sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side included industry experts, such as Chief Executive Officers (CEOs), Vice Presidents (VPs), marketing directors, technology and innovation directors, and related key executives from various key companies and organizations operating in the AI in oncology market.

      After the complete market engineering (calculations for market statistics, market breakdown, market size estimations, market forecasting, and data triangulation), extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. Primary research was also undertaken to identify the segmentation types, industry trends, competitive landscape of AI in oncology solutions offered by various market players, and key market dynamics, such as drivers, restraints, opportunities, challenges, industry trends, and key player strategies.

      In the complete market engineering process, the top-down and bottom-up approaches and several data triangulation methods were extensively used to perform the market estimation and market forecasting for the overall market segments and subsegments listed in this report. Extensive qualitative and quantitative analysis was performed on the complete market engineering process to list the key information/insights throughout the report.

      Breakdown of Primary Participants:

      AI in Oncology Market

      Note 1: Others include sales managers, marketing managers, and product managers.

      Note 2: Tiers of companies are defined based on their total revenues in 2023. Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = < USD 500 million.

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the AI in oncology. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry and markets have been identified through extensive secondary research.
      • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
      AI in Oncology Market

      Data Triangulation

      After arriving at the overall market size using the market size estimation processes explained above, the market was split into several segments and subsegments. The data triangulation and market breakup procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      AI I in oncology is the utilization of AI tools such as machine learning, natural language processing, and computer vision, among others to analyze genomic data and large gene mutations that are unique to an individual’s cancer profile. These AI tools are adopted by various end-users including labs, research centers, hospitals, and biotechnology & pharmaceuticals, among others to address the global cancer burden and the need for precision medicine in oncology.

      Further, AI boosts the speed and accuracy of cancer diagnosis and screening. The major developments include:

      • Pathologists can detect malignancy in prostate biopsy photos with the help of FDA-approved AI software.
      • AI quickly analyzes medical pictures, such as mammograms, increasing radiologists' productivity and enhancing risk assessment and detection of breast cancer.
      • Deep learning is used by NCI scientists to automatically detect precancerous cervical lesions as part of their efforts to improve cervical and prostate cancer screening.

      Stakeholders

      • Clinical/Physician Centers
      • AI Providers
      • Clinical Research Organizations
      • Pharmaceutical/Biopharmaceutical Companies
      • Research and Development (R&D) Companies
      • Business Research and Consulting Service Providers
      • Medical Research Laboratories
      • Academic Medical Centers/Universities/Hospitals
      • Government Agencies
      • Regulatory Agencies
      • Clinical Researchers
      • Clinical Research Organizations
      • Accountable Care Organizations
      • Investors and Venture Capitalists

      Report Objectives

      • To define, describe, and forecast the AI in oncology market based on player type, application, cancer type, technology, deployment model, end user, and region
      • To provide detailed information about the major factors (drivers, opportunities, restraints, and challenges) influencing the growth of the market
      • To analyze opportunities for stakeholders by identifying the high-growth segments of the market
      • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America
      • To analyze subsegments of the market with respect to individual growth trends, prospects, and contributions to the overall market
      • To profile the key players and comprehensively analyze their market sizes and core competencies
      • To track and analyze competitive developments such as acquisitions, collaborations, agreements, mergers, product launches & updates, partnerships, expansions, and other recent developments in the market globally

      Get the Full AI in Oncology Market Report

      Full forecast, segment splits, and company analysis for all AI in Oncology Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status